Insights
Search Results
Client Highlights
6.30.26
Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric
On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
6.04.26
Wilson Sonsini Advises Cloudflare on Acquisition of VoidZero
On June 4, 2026, Cloudflare, a leading connectivity cloud company, announced it has acquired VoidZero, an open source-first company behind the next-generation JavaScript tooling ecosystem Vite. The acquisition will unify VoidZero’s high-performance tooling including the Vite build tool, Vitest test runner, Rust-based Rolldown bundler, and Oxc toolchain natively into the Cloudflare ecosystem. Wilson Sonsini Goodrich & Rosati advised Cloudflare on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
4.21.26
Wilson Sonsini Advises Novo Holdings, Norwest, and Platanus on Ray Therapeutics’ $125 Million Series B
On April 21, 2026, Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degenerations, announced the closing of an upsized and oversubscribed $125 million Series B financing. The round was led by Janus Henderson Investors, with participation from additional new investors Adage Capital Management, Franklin Templeton, Invus, and Marshall Wace. The financing includes strong follow-on support from existing investors 4BIO Capital, Deerfield Management, MRL Ventures Fund (the therapeutics-focused corporate venture arm of Merck & Co), Norwest, Novo Holdings A/S, and Platanus. Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S, Norwest, and Platanus on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.30.26
Wilson Sonsini Advises Octopus Energy on Majority Stake Acquisition of Uplight
On March 24, 2026, Octopus Energy Group, a global clean energy and technology business driving the affordable, green energy system of the future, will cement its expansion in the U.S. by acquiring a majority stake in Uplight, a leading provider of customer engagement and flexibility management solutions that rapidly transform customer participation into dependable grid capacity. The deal is made in partnership with Schneider Electric, a global energy technology leader trusted by utilities worldwide, which will remain as a significant minority partner. The transaction is subject to customary regulatory approvals and is expected to complete later this year. Wilson Sonsini Goodrich & Rosati advised Octopus Energy on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.12.26
Wilson Sonsini Advises Replit on $400 Million Series D
On March 11, 2026, Georgian, a growth-stage B2B investor, announced it has led a $400 million Series D investment in Replit, an AI-powered development platform, valuing the company at $9 billion. G Squared, Prysm Capital, Coatue, Andreessen Horowitz (a16z), Craft Ventures, Y Combinator, Accenture Ventures, Okta Ventures, and Databricks Ventures also participated in the round. Wilson Sonsini Goodrich & Rosati advised Replit on the transaction.
Client Highlights
2.25.26
Wilson Sonsini Advises SambaNova on $350 Million Series E Financing
On February 24, 2026, SambaNova, a leader in next‑generation AI infrastructure, announced that it has raised more than $350 million in investment from new and existing investors. The oversubscribed Series E round was led by Vista Equity Partners and Cambium Capital, with strong participation from Intel Capital. Wilson Sonsini Goodrich & Rosati advised SambaNova on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.